CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical and radiation oncologists, hematology-oncology fellows, urologists and other healthcare providers involved in the treatment of prostate cancer.
  
  LEARNING OBJECTIVES

  • Appraise published research and current guideline recommendations on the optimal management of biochemical recurrence after local treatment for prostate cancer, and counsel appropriate patients regarding the potential benefits of systemic therapy.
  • Evaluate the published research database supporting the FDA approvals of secondary hormonal agents in the management of nonmetastatic castration-resistant prostate cancer (CRPC), and apply this information in the discussion of nonresearch treatment options with patients.
  • Explore available data with treatment intensification using cytotoxic therapy, secondary hormonal therapy or combinations of these approaches for metastatic hormone-sensitive prostate cancer, and effectively integrate these strategies into clinical management algorithms.
  • Establish an evidence-based approach to the selection and sequencing of therapeutic options for patients with metastatic CRPC (mCRPC), considering age, comorbidities, prior therapeutic exposure and other clinical and biologic factors.
  • Assess available research with PARP inhibitors alone or in combination with secondary hormonal therapies for mCRPC, and discern how to optimally incorporate these agents and regimens into the clinical management algorithm.
  • Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of this CME activity, which includes participation in the evaluation components and a short post-test, enables the participant to earn up to 2.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASCO2023/Prostate/Video/CME.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Emmanuel S Antonarakis, MD
  Clark Endowed Professor of Medicine
  Division of Hematology, Oncology and Transplantation
  University of Minnesota
  Minneapolis, Minnesota
  
  Advisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Merck, Sanofi, Tempus; Consulting Agreements: Aadi Bioscience, AIkido Pharma Inc, Blue Earth Diagnostics, CM Propel, Corcept Therapeutics, EcoR1 Capital LLC, Foundation Medicine, HOOKIPA Pharma Inc, KeyQuest Health, MacroGenics Inc, Menarini Silicon Biosystems, z-Alpha; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Constellation Pharmaceuticals, Merck, Orion Corporation, Sanofi; Patent Holder: QIAGEN; Nonrelevant Financial Relationship: European Association of Urology (UROwebinar), Ismar Healthcare NV.
  
  Prof Karim Fizazi, MD, PhD
  Head of Service and Full Professor
  Institut Gustave Roussy
  University of Paris Saclay
  Villejuif, France
  
  Advisory Committee: Arvinas, CureVac, Orion Corporation; Data and Safety Monitoring Board/Committee: Lilly; Consulting Agreements (with My Institution): Advanced Accelerator Applications, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Daiichi Sankyo Inc, Janssen Biotech Inc, Merck Sharp & Dohme LLC, Novartis, Pfizer Inc, Sanofi.
  
  Rana R McKay, MD
  Associate Professor of Medicine and Urology
  Associate Director, Translational Sciences
  Co-Lead, Genitourinary Oncology Program
  University of California San Diego
  Moores Cancer Center
  La Jolla, California
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Caris Life Sciences, Dendreon Pharmaceuticals Inc, Exelixis Inc, Johnson & Johnson Pharmaceuticals, Lilly, Merck, Myovant Sciences, Novartis, Pfizer Inc, Sanofi, Seagen Inc, Sorrento Therapeutics, Telix Pharmaceuticals Limited, Tempus; Contracted Research: AstraZeneca Pharmaceuticals LP, Exelixis Inc, Oncternal Therapeutics, Tempus.
  
  Alicia K Morgans, MD, MPH
  Associate Professor of Medicine
  Harvard Medical School
  Medical Director, Survivorship Program
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  
  Consulting Agreements: Advanced Accelerator Applications, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Exelixis Inc, Foundation Medicine, Janssen Biotech Inc, Lantheus, Merck, Myovant Sciences, Novartis, Pfizer Inc, Sanofi, Telix Pharmaceuticals Limited; Contracted Research: Bayer HealthCare Pharmaceuticals, Myovant Sciences, Pfizer Inc; Data and Safety Monitoring Board/Committee: Gilead Sciences Inc.
  
  A Oliver Sartor, MD
  Director of Radiopharmaceutical Clinical Trials
  Professor, Department of Oncology
  Mayo Clinic in Rochester, Minnesota
  Rochester, Minnesota
  
  Consultant: Advanced Accelerator Applications, Amgen Inc, ARTbio, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Clarity Pharmaceuticals, Clovis Oncology, Constellation Pharmaceuticals, Convergent Therapeutics Inc, Dendreon Pharmaceuticals Inc, EMD Serono Inc, Foundation Medicine, Fusion Pharmaceuticals, Genzyme Corporation, Hengrui Therapeutics Inc, ITM Isotopen Technologien München AG, Janssen Biotech Inc, Merck, Morphimmune, Myovant Sciences, Myriad Genetic Laboratories Inc, Noria Therapeutics Inc, NorthStar Rx LLC, Novartis, Noxopharm, Pfizer Inc, POINT Biopharma, Progenics Pharmaceuticals Inc, Ratio Therapeutics, Sanofi, Telix Pharmaceuticals Limited, TeneoBio, Tessa Therapeutics, Theragnostics, z-Alpha; Equity Interests: Telix Pharmaceuticals Limited; Grant/Research Support: Advanced Accelerator Applications, Amgen Inc, Arvinas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Constellation Pharmaceuticals, Invitae, Janssen Biotech Inc, Lantheus, Merck, Novartis, Progenics Pharmaceuticals Inc, TeneoBio; Nonrelevant Financial Relationship: Ratio Therapeutics.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Lilly, Merck, and Sanofi.
  
  Release date: July 2023
  Expiration date: July 2024
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.